Sun Pharma gets CDSCO nod for Tofacitinib
|
Overview
In a significant development, the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has granted approval to pharma major Sun Pharmaceuticals to manufacture and market Tofacitinib ER Tablets 11mg for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis.
This came after the drug maker Sun Pharma presented the proposal for manufacturing and marketing of Tofacitinib ER Tablets 11mg along with bioavailability (BE) Study report before the committee.
For more information check out the full story on the link below:
Speakers
Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
